Pharmacologic treatments for covid-19 patients

Clazakizumab vs Placebo

This comparison will not be updated. Last search date 14 Dec, 2022

On March 18th, 2021, we published results of the living systematic review on IL-6 blocking agents which included all preprints and published trials published online up to February 11th, 2021.

We updated the the evidence on the effectiveness and safety of IL-6 blocking agents compared to standard care alone or to a placebo for people with COVID-19. On June 1, 2023, an update of the systematic review on IL-6 blocking agents was published. It included all preprints and published trials published online up to June 7, 2022.

Hospitalized patients

Forest plots
(last update: 2022-05-29)

Summary of findings
(last update: 2022-09-27)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=735

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04343989
Lonze B, Crit Care Med, 2022
Full text
Commentary
Mixed

Clazakizumab 25

Placebo

RCT Patients with confirmed COVID-19 (moderate-severe-critical) admitted to multiple centers in the USA. N=178
Some concerns
Details

Full description

NCT04348500
Jordan S, Unpublished, 2021
Full text
Private

Clazakizumab

Placebo

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in USA. N=17
Some concerns
Details

Full description